Samiksha Jaiswal (Editor)

Muraglitazar

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
ATC code  None
CAS Number  331741-94-7
ChemSpider  178524
Legal status  Development terminated
PubChem CID  206044
Molar mass  516.54 g/mol
Muraglitazar httpsuploadwikimediaorgwikipediacommonsthu
Synonyms  2-[(4-Methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid

How to pronounce muraglitazar


Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARĪ± and PPARĪ³.

The drug had completed phase III clinical trials, however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development.

Data on muraglitazar is relatively sparse due to the recent introduction of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone.

References

Muraglitazar Wikipedia


Similar Topics
Snehituda
Emanuele Bardelloni
Myint Naing
Topics
 
B
i
Link
H2
L